Developing a national collaborative study system for rare genetic diseases

Michael S. Watson, Charles Epstein, R. Howell, Marilyn C. Jones, Bruce R. Korf, Edward R B McCabe, Joe Leigh Simpson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

There are thousands of rare genetic diseases and many genetic and nongenetic contributors to common genetic diseases. The evidence base that is currently available about the great majority of these conditions is limited to case studies and relatively small observational study sets derived from one or several institutions. Hence, the statistical power in any one study is usually quite limited. Further, in the absence of organized registries and data collection on particular patient groups, the information available is weak and the patient resources that are available are limited. It is only through organized and coordinated clinical investigation systems that a sufficient number of patients with these diseases can be accumulated to provide the statistical power needed to inform about clinical history of treated and untreated forms, provide the resources needed for clinical trials of new tests and treatments, provide a sufficiently powered evidence base for public health decision-making and other uses. The meeting in which these issues were raised resulted in a set of proposed principles and associated recommendations as to how best to achieve the vision of creating an extensive and comprehensive collaboration of professional and lay communities to enable translational research to improve clinical care and therapies for persons with rare genetic diseases.

Original languageEnglish
Pages (from-to)325-329
Number of pages5
JournalGenetics in Medicine
Volume10
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Inborn Genetic Diseases
Rare Diseases
Translational Medical Research
Observational Studies
Registries
Decision Making
Public Health
Clinical Trials
Therapeutics

Keywords

  • Clinical investigation
  • Genetics
  • Rare diseases
  • Research infrastructure

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Watson, M. S., Epstein, C., Howell, R., Jones, M. C., Korf, B. R., McCabe, E. R. B., & Simpson, J. L. (2008). Developing a national collaborative study system for rare genetic diseases. Genetics in Medicine, 10(5), 325-329. https://doi.org/10.1097/GIM.0b013e31817b80fd

Developing a national collaborative study system for rare genetic diseases. / Watson, Michael S.; Epstein, Charles; Howell, R.; Jones, Marilyn C.; Korf, Bruce R.; McCabe, Edward R B; Simpson, Joe Leigh.

In: Genetics in Medicine, Vol. 10, No. 5, 01.05.2008, p. 325-329.

Research output: Contribution to journalArticle

Watson, MS, Epstein, C, Howell, R, Jones, MC, Korf, BR, McCabe, ERB & Simpson, JL 2008, 'Developing a national collaborative study system for rare genetic diseases', Genetics in Medicine, vol. 10, no. 5, pp. 325-329. https://doi.org/10.1097/GIM.0b013e31817b80fd
Watson, Michael S. ; Epstein, Charles ; Howell, R. ; Jones, Marilyn C. ; Korf, Bruce R. ; McCabe, Edward R B ; Simpson, Joe Leigh. / Developing a national collaborative study system for rare genetic diseases. In: Genetics in Medicine. 2008 ; Vol. 10, No. 5. pp. 325-329.
@article{c2847f96a8a64d728ddea8924faf2714,
title = "Developing a national collaborative study system for rare genetic diseases",
abstract = "There are thousands of rare genetic diseases and many genetic and nongenetic contributors to common genetic diseases. The evidence base that is currently available about the great majority of these conditions is limited to case studies and relatively small observational study sets derived from one or several institutions. Hence, the statistical power in any one study is usually quite limited. Further, in the absence of organized registries and data collection on particular patient groups, the information available is weak and the patient resources that are available are limited. It is only through organized and coordinated clinical investigation systems that a sufficient number of patients with these diseases can be accumulated to provide the statistical power needed to inform about clinical history of treated and untreated forms, provide the resources needed for clinical trials of new tests and treatments, provide a sufficiently powered evidence base for public health decision-making and other uses. The meeting in which these issues were raised resulted in a set of proposed principles and associated recommendations as to how best to achieve the vision of creating an extensive and comprehensive collaboration of professional and lay communities to enable translational research to improve clinical care and therapies for persons with rare genetic diseases.",
keywords = "Clinical investigation, Genetics, Rare diseases, Research infrastructure",
author = "Watson, {Michael S.} and Charles Epstein and R. Howell and Jones, {Marilyn C.} and Korf, {Bruce R.} and McCabe, {Edward R B} and Simpson, {Joe Leigh}",
year = "2008",
month = "5",
day = "1",
doi = "10.1097/GIM.0b013e31817b80fd",
language = "English",
volume = "10",
pages = "325--329",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Developing a national collaborative study system for rare genetic diseases

AU - Watson, Michael S.

AU - Epstein, Charles

AU - Howell, R.

AU - Jones, Marilyn C.

AU - Korf, Bruce R.

AU - McCabe, Edward R B

AU - Simpson, Joe Leigh

PY - 2008/5/1

Y1 - 2008/5/1

N2 - There are thousands of rare genetic diseases and many genetic and nongenetic contributors to common genetic diseases. The evidence base that is currently available about the great majority of these conditions is limited to case studies and relatively small observational study sets derived from one or several institutions. Hence, the statistical power in any one study is usually quite limited. Further, in the absence of organized registries and data collection on particular patient groups, the information available is weak and the patient resources that are available are limited. It is only through organized and coordinated clinical investigation systems that a sufficient number of patients with these diseases can be accumulated to provide the statistical power needed to inform about clinical history of treated and untreated forms, provide the resources needed for clinical trials of new tests and treatments, provide a sufficiently powered evidence base for public health decision-making and other uses. The meeting in which these issues were raised resulted in a set of proposed principles and associated recommendations as to how best to achieve the vision of creating an extensive and comprehensive collaboration of professional and lay communities to enable translational research to improve clinical care and therapies for persons with rare genetic diseases.

AB - There are thousands of rare genetic diseases and many genetic and nongenetic contributors to common genetic diseases. The evidence base that is currently available about the great majority of these conditions is limited to case studies and relatively small observational study sets derived from one or several institutions. Hence, the statistical power in any one study is usually quite limited. Further, in the absence of organized registries and data collection on particular patient groups, the information available is weak and the patient resources that are available are limited. It is only through organized and coordinated clinical investigation systems that a sufficient number of patients with these diseases can be accumulated to provide the statistical power needed to inform about clinical history of treated and untreated forms, provide the resources needed for clinical trials of new tests and treatments, provide a sufficiently powered evidence base for public health decision-making and other uses. The meeting in which these issues were raised resulted in a set of proposed principles and associated recommendations as to how best to achieve the vision of creating an extensive and comprehensive collaboration of professional and lay communities to enable translational research to improve clinical care and therapies for persons with rare genetic diseases.

KW - Clinical investigation

KW - Genetics

KW - Rare diseases

KW - Research infrastructure

UR - http://www.scopus.com/inward/record.url?scp=44449152155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449152155&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e31817b80fd

DO - 10.1097/GIM.0b013e31817b80fd

M3 - Article

VL - 10

SP - 325

EP - 329

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 5

ER -